Current Consultations
Public consultations enable the HPRA to identify the needs and expectations of stakeholders so that we may incorporate their views into the way our services are planned and delivered.
Closed consultations
Below are public consultations that have recently closed. Please see here for older consultations.
Public consultation on proposed fees 2022: Veterinary medicinal products
Start Date of Consultation: 6th October 2021
Closing Date of Consultation: 5th November 2021
The public consultation on proposed fees for Veterinary medicines for 2022 was closed on 5th November 2021. The HPRA would like to thank everybody who contributed to the process. Below is a document summarising the outcome of the consultation process.
Outcome of the Process - Public Consultation on Proposed Fees for 2022
Public consultation on veterinary medicines fees 2022
HPRA
16th November 2021
Public consultation on proposed fees 2022: Human Medicines, Compliance Activities, Blood, Tissue Establishments and Organs and Medical Devices
Start Date of Consultation: 1st October 2021
Closing Date of Consultation: 29th October 2021
The public consultation on proposed fees for Human Medicines, Compliance Activities, Blood, Tissue Establishments and Organs for 2022 was closed on 29th October 2021. The HPRA would like to thank everybody who contributed to the process. Below is a document summarising the outcome of the consultation process.
Outcome of the Process - Public Consultation on Proposed Fees for 2022
Public consultation on human medicines and medical device fees
HPRA
16th November 2021
Public consultation on the proposal for Clinical Trials fees 2022
Start Date of Consultation: 10th September 2021
Closing Date of Consultation: 8th October 2021
The public consultation on proposed fees for Clinical Trials for 2022 was closed on 8th October 2020. The HPRA would like to thank everybody who contributed to the process. Below is a document summarising the outcome of the consultation process.
Outcome of the Process - Public Consultation on Proposed Clinical Trial Fees for 2022
Public Consultation on Clinical Trial Fees 2022
HPRA
2nd November 2021
Public consultation on proposed fees 2021: Human medicines, Compliance activities, Blood, Tissue establishments and Organs
Start Date of Consultation: 1st October 2020
Closing Date of Consultation: 30th October 2020
The public consultation on proposed fees for Human Medicines, Compliance Activities, Blood, Tissue Establishments and Organs for 2021 was closed on 30 October 2020. The HPRA would like to thank everybody who contributed to the process. Below is a document summarising the outcome of the consultation process.
Outcome of the Process - Public Consultation on Proposed Fees for 2021
Public consultation on human medicines fees 2021
HPRA
04 December 2020
Public consultation on proposed medical devices fees 2021
Start Date of Consultation: 1st October 2020
Closing Date of Consultation: 30th October 2020
The public consultation on proposed fees for medical devices for 2021 was closed on 30 October 2020. The HPRA would like to thank everybody who contributed to the process. Below is a document summarising the outcome of the consultation process.
Outcome of the Process - Public consultation on proposed medical device fees 2021 Public consultation on medical device fees 2021
HPRA
01 December 2020
HPRA strategic plan 2021-2025
Consultation closing date: 3 January 2020
The HPRA has undertaken a public consultation on the HPRA Strategic Plan 2021-2025. The consultation period has now ended. A response document on the outcome of the consultation will be published in due course.
Guide to biosimilars for healthcare professionals
Consultation closing date: 23 December 2019
The HPRA Guide to Biosimilars for Healthcare Professionals and Patients has been updated. The guide was originally published in 2015. Since then, there has been an increase in clinical and regulatory experience with this class of medicines as well as a growing body of scientific literature. The updated guide is now aimed solely at healthcare professionals, as the HPRA published a separate guide and information video for patients in 2017. The updated guide also provides further clarification of the HPRA’s position on interchangeability, switching and substitution.
The guide was open for public consultation to gather feedback from stakeholders as to whether it provided enough relevant information about biosimilars to meet their needs. The content of the guide has been amended to take account of the comments received as appropriate.
Outcome of the process
Guide to biosimilars for healthcare professionals v3 (5 August 2020)